Bethany Halford
Science Writer and Senior Correspondent at C&EN
Science writer (she/her) at @cenmag. Interested in molecules and molecule makers. Any opinions here are mine.
Articles
-
1 week ago |
pubs.acs.org | Bethany Halford
Monday, April 14, 2025 Please be aware that pubs.acs.org is undergoing maintenance from Saturday February 1 to Monday Febraury 3, that may have an impact on your experience. During this time, you may not be able to access certain features like login, purchasing single articles, saving searches or running existing saved searches, modifying your e-Alert preferences, or accessing Librarian administrative functions. We appreciate your patience as we continue to improve the ACS Publications platform.
-
2 weeks ago |
cen.acs.org | Bethany Halford
Pushing the known limits of lanthanide oxidation, chemists have isolated praseodymium (Pr) in the +5 oxidation state. WhilePr 5+ compounds have been observed in the gas phase and in noble gas matrix isolation conditions before, this is the first time chemists have been able to characterize one using X-ray crystallography. The finding suggests that chemists should shift how they situate lanthanides in the periodic table.
-
1 month ago |
cen.acs.org | Bethany Halford
In celebrity-filled Los Angeles, Frances H. Arnold can walk down the street in relative anonymity. That's not to say she's not famous. Fans of the popular TV show The Big Bang Theory might recognize her from one episode (in which she played herself), and art lovers might have seen her photo in the collection of the Smithsonian Institution's National Portrait Gallery. But in Tinseltown, she can go about her daily routine in relative peace.
-
1 month ago |
cen.acs.org | Bethany Halford
A molecule that targets the same receptor as the active ingredient in cannabis could lead scientists to new drugs for chronic pain. Chemists designed the compound, known as VIP36, to bind cannabinoid receptor 1 (CB1) in the body but not in the brain. This design prevents the molecule from having psychoactive side effects. In mouse studies, VIP36 treated inflammatory pain, nerve pain, and migraines ( Nature 2025, DOI: 10.1038/s41586-025-08618-7).
-
1 month ago |
cen.acs.org | Bethany Halford
An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on the horizon. Pfizer-the maker of Paxlovid-has begun Phase 3 clinical trials of a next-generation coronavirus antiviral, ibuzatrelvir. Ibuzatrelvir offers several advantages over its predecessor. It doesn't have the drug-drug interactions that prevent many people with COVID-19 from taking Paxlovid.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 3K
- Tweets
- 4K
- DMs Open
- Yes
Check out this supramolecular snub cube. Cool chemistry from Huang Wu and the late @sirfrasersays of the University of Hong Kong along with Wenping Hu and Yu Wang of Tianjin University. My latest in @cenmag https://t.co/SOfaDLlQ0o https://t.co/UxIpOBSuZb
So sad to hear we've lost @sirfrasersays. He was always generous to me as a reporter for @cenmag and kind to me as a human being. My thoughts are with his family, friends, and colleagues. https://t.co/92uAzyT6z0
With apologies to @ChappellRoan and @LongLabCal Baby, do you like this zinc(H)? We made this MOF to capture C(O2) Over 199 degrees When you’re tackling global warming, tackling global warming Thanks to my @cenmag colleagues who encouraged the lede https://t.co/pV9ohu7yyy